Abstract
Stereotactic body radiation therapy (SBRT) is a very effective way to treat early stage non-small cell lung cancer (NSCLC) and small oligometastatic lung lesions with consistently high rates of local control, but both local and regional/distant recurrences still occur. The management of recurrences remains unsettled and may entail repeat SBRT, conventionally fractionated external beam RT (EF-EBRT), chemotherapy or surgery. Most patients with local recurrences [within the initial planning target volume (PTV)] can be salvaged successfully with good cancer specific survival. Nonetheless, proximity of the initial SBRT delivery to organs at risk (ribs, blood vessels, airways) may make retreatment more difficult. With attention to detail and careful patient selection, both surgery and reirradiation can be performed safely and effectively. Strategies for management of regional (nodal) recurrences may require conventional therapies tailored to the patterns of failure. The role of immunotherapy in salvage has not been elucidated as yet. We review here data on the available literature concerning salvage of SBRT lung patients.
| Original language | English |
|---|---|
| Pages (from-to) | S213-S221 |
| Journal | Translational Lung Cancer Research |
| Volume | 8 |
| DOIs | |
| State | Published - Sep 1 2019 |
Bibliographical note
Publisher Copyright:© Translational lung cancer research. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Failure
- Salvage
- Stereotactic body radiation therapy (SBRT)
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver